CHENGDU, China, April 14, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech' or the 'Company', 6990.HK) announced that results from both the ovarian cancer cohort ...

DNADX high scores predicted improved PFS, supporting genomic instability and DNA repair deficiency as biologically relevant ...

Trastuzumab pamirtecan, being developed under a 2023 partnership between BioNTech and DualityBio, elicited a 44.1% overall ...

SCLC, addressing a high-relapse setting with limited second-line efficacy and modest survival benefit. Ifinatamab deruxtecan ...

Phase 1/2 RAINFOL™-01 data showed the combination ofrinatabart sesutecan (Rina-S®) and bevacizumab was tolerable, with no new safety signals in patients with advanced ovarian c ...

Add Yahoo as a preferred source to see more of our stories on Google. Trastuzumab pamirtecan is intended for treating ...

At AACR 2026, the Genialis™ Supermodel–powered RNA survival model outperforms standard of care in real-world clinical data, establishing a scalable biomarker framework for ADC drug developmentBOSTON-- ...

This antibody-drug conjugate targets a specific protein associated with poor prognosis in patients whose disease progressed after platinum-based chemotherapy.

Lung01 Phase 2 trial, with support from IDeate-PanTumor01 Phase 1/2 trialIf approved, ifinatamab deruxtecan would be a first-in-class B7-H3 directed DXd antibody drug conjugate for these patients ...

Gilead's $5B Tubulis deal expands its ADC pipeline, boosting oncology ambitions as the company accelerates strategic ...

MUC16 is highly and stably expressed in the most aggressive and most common subtypes of endometrial cancer Findings support Whitehawk's development of MUC16-directed ADC, HWK-016, currently being ...

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SIM0505 for the treatment of women with platinum resistant ovarian cancer (PROC) Phase 1 data for SIM0505 to be ...